Drugs / TEMUTERKIB
TEMUTERKIB
Trials 9 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04391595 | Jul 2020 → Jul 2023 | glioblastoma | Nader Sanai | Completed | No outcome recorded |
| Phase 15 trials | ||||||
| Phase 1 | NCT04916236 | Mar 2022 → Jul 2024 | colorectal cancer, malignant pancreatic neoplasm, non-small cell lung carcinoma | The Netherlands Cancer Institute | Terminated | No outcome recorded |
| Phase 1 | NCT04081259 | Jul 2020 → Aug 2023 | acute myeloid leukemia | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 1 | NCT04043845 | Feb 2020 | B-cell chronic lymphocytic leukemia, Waldenstrom macroglobulinemia, mantle cell lymphoma, marginal zone lymphoma | Dana-Farber Cancer Institute | Withdrawn | No outcome recorded |
| Phase 1 | NCT04033341 | Aug → Sep 2019 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02857270 | Sep 2016 → Feb 2021 | colorectal cancer, metastatic melanoma, non-small cell lung carcinoma | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04616183 | Dec 2020 → Dec 2028 expected | colon adenocarcinoma, rectum adenocarcinoma | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04534283 | Oct 2020 → Aug 2023 | metastatic malignant neoplasm | Anita Turk | Terminated | No outcome recorded |
| Phase 2 | NCT04386057 | May 2020 → Aug 2023 | malignant pancreatic neoplasm | Dana-Farber Cancer Institute | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TEMUTERKIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650285 ↗ |
| Known as | LY-3214996 MESYLATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650285 ↗ |
| Known as | LY-3518429 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650285 ↗ |
| Known as | LY3214996 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04534283 ↗ |
| Known as | TEMUTERKIB MESYLATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650285 ↗ |
| Action | Inhibit | “Here, we report identification and activity of LY3214996, a potent, selective, ATP-competitive ERK inhibitor.” PMID 31744895 ↗ Nov 2019 |
| Modality | Small molecule | — CHEMBL4650285 ↗ |
| Route | Oral | “Administered orally” NCT04033341 ↗ |